

1 **Title: Predominance of multidrug-resistant (MDR) bacteria causing urinary tract**  
2 **infections (UTIs) among symptomatic patients in East Africa: a call for action**

3 **Authors:** Antonio Maldonado-Barragán<sup>1†\*</sup>, Stephen E. Mshana<sup>2†\*</sup>, Katherine Keenan<sup>6</sup>, Xuejia Ke<sup>7</sup>,  
4 Stephen H. Gillespie<sup>1</sup>, John Stelling<sup>3</sup>, John Maina<sup>4</sup>, Joel Bazira<sup>5</sup>, Ivan Muhwezi<sup>5</sup>, Martha F. Mushi<sup>2</sup>,  
5 Dominique L. Green<sup>6</sup>, Mike Kesby<sup>6</sup>, Andy G. Lynch<sup>1</sup>, Wilber Sabiiti<sup>1</sup>, Derek J. Sloan<sup>1</sup>, Alison  
6 Sandeman<sup>1</sup>, John Kiiru<sup>4</sup>, Benon Asiimwe<sup>8</sup>, Matthew T. G. Holden<sup>1</sup>, HATUA consortium.

7  
8 †These authors contributed equally to this work and share first authorship.

9  
10 **Affiliations:**

11 <sup>1</sup>School of Medicine, University of St Andrews, St Andrews, Fife, KY16 9TF, UK

12 <sup>2</sup>Department of Microbiology and Immunology, Weill Bugando School of Medicine, Catholic University of Health and  
13 Allied Sciences, Mwanza P.O. Box 1464, Tanzania

14 <sup>3</sup>Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA

15 <sup>4</sup>Centre for Microbiology Research, Kenya Medical Research Institute, Nairobi, Kenya

16 <sup>5</sup>Department of Microbiology and Immunology, Mbarara University of Science and Technology, Mbarara, Uganda

17 <sup>6</sup>School of Geography and Sustainable Development, University of St Andrews, St Andrews, KY16 8AL, Fife, UK

18 <sup>7</sup>School of Biology, University of St Andrews, St Andrews, KY16 9TH, Fife, UK

19 <sup>8</sup>Department of Medical Microbiology, College of Health Sciences, Makerere University, Kampala, Uganda

20

21 **Corresponding (s) author (s):**

22 Antonio Maldonado-Barragán\*; e-mail: [maldoantonio@gmail.com](mailto:maldoantonio@gmail.com)

23 Stephen E. Mshana\*; e-mail: [stephen72mshana@gmail.com](mailto:stephen72mshana@gmail.com)

24

25 **HATUA consortium includes everyone listed above, plus:**

26 Blandina T. Mmbaga (Kilimanjaro Clinical Research Institute and Kilimanjaro Christian Medical

27 University College, Tanzania), John Mwaniki (KEMRI, Kenya), Stella Neema (Makerere University,

28 Uganda), Joseph R. Mwanga (Catholic University of Health and Allied Sciences, Tanzania), Arun

29 Gonzales Decano (University of St Andrews, UK), V. Anne Smith (University of St Andrews, UK),

30 Alison Elliott (London School of Hygiene & Tropical Medicine, UK), Gibson Kibiki (Africa

31 Research Excellence Fund), David Aanensen (University of Oxford, UK).

32

33 **Author contributions**

34 AM: Formal analysis, Data curation, Writing – original draft preparation, Writing – review and editing

35 SEM: Conceptualisation, Formal analysis, Data curation, Writing – original draft preparation, Writing – review  
36 and editing.

37 XK: Formal analysis, data curation; Writing – review and editing

38 KK: Conceptualisation, Formal analysis, data curation; Writing – review and editing, supervision

39 SG: Methodology; Validation; Writing – review and editing

40 JS: Methodology; Validation; Writing – review and editing

41 JM: Methodology; Investigation; Data curation; Writing – review and editing

42 JB: Methodology; Investigation; Data curation

43 IM: Methodology; Investigation; Data curation

44 MM: Methodology; Investigation; Data curation

45 DLG: Data curation

46 MK: Conceptualisation; Methodology; Writing – review and editing

47 AGL: Conceptualisation; Methodology; Writing – review and editing

48 WS: Conceptualisation; Methodology; Writing – review and editing

49 DJS: Conceptualisation; Methodology; Writing – review and editing

50 AS: Coordinated the study; Writing – review and editing

51 JK: Conceptualisation; Methodology; Led data collection in Kenya

52 BA: Conceptualisation; Methodology; Led data collection in Uganda

53 MH: Led project conceptualisation; Methodology, Funding acquisition; Writing – review and editing

54

55

56

57

58

59

60

## 61 **Abstract**

62 In low- and middle-income countries, antibiotics are often prescribed for patients with symptoms of  
63 urinary tract infections (UTIs) without microbiological confirmation. Inappropriate antibiotic use can  
64 contribute to antimicrobial resistance (AMR) and the selection of multi-drug resistant (MDR)  
65 bacteria. Data on antibiotic susceptibility patterns of cultured bacteria are important in drafting  
66 empirical treatment guidelines and monitoring resistance trends, which can prevent the spread of  
67 AMR. In East Africa, antibiotic susceptibility data are sparse. To fill the gap, this study reports  
68 common microorganisms and their susceptibility patterns isolated from patients with UTI-like  
69 symptoms in Kenya, Tanzania, and Uganda in 2019-2020. Microbiologically confirmed UTI was  
70 observed in 2,653 (35.0%) of the 7583 patients studied. The predominant bacteria were *Escherichia*  
71 *coli* (37.0%), *Staphylococcus* spp. (26.3%), *Klebsiella* spp. (5.8%) and *Enterococcus* spp. (5.5%). *E.*  
72 *coli* contributed 982 of the isolates with an MDR proportion of 52.2%. *Staphylococcus* spp.  
73 contributed 697 of the isolates with an MDR rate of 60.3%. The overall proportion of MDR bacteria  
74 (n=1,153) was 50.9%. MDR bacteria are common causes of UTI in patients attending healthcare  
75 centres in East African countries, which emphasizes the need for investment in laboratory culture  
76 capacities and diagnostic algorithms to improve accuracy of diagnosis that will lead to appropriate  
77 antibiotic uses to prevent and control AMR.

78  
79 **Keywords:** Urinary Tract Infection; Antimicrobial resistance; Antibacterial resistance; Multi-drug  
80 resistance; Pathogen-antibiotic combinations; East Africa.

81

82

## 83 **1. Introduction**

84 Increase of antimicrobial resistance (AMR) is currently considered one of the top 10 global public  
85 health threats [1]. In 2019, there were an estimated 4.95 million deaths associated with antibacterial  
86 resistance (ABR) including 1.27 million deaths directly attributable to ABR [2]. Among all world  
87 regions, Sub-Saharan Africa has the largest burden of ABR-attributable deaths [2], although most  
88 contemporary ABR estimates in that region are based on incredibly sparse data [2,3,4]. This serious  
89 threat requires a better assessment of ABR to understand the current and future burden of AMR and  
90 to direct the use of antibiotics (ABs) more effectively. This motivated the formation of the  
91 interdisciplinary consortium “Holistic Approach to Unravel Antibacterial Resistance in East Africa”  
92 (HATUA), which aimed to explore the burden and drivers of ABR associated with urinary tract  
93 infections (UTIs) in three East African countries, Kenya, Tanzania, and Uganda [5].

94

95 UTI is an inflammatory response of the urothelium to bacterial invasion and is considered the most  
96 frequent community-acquired bacterial infection in the world, affecting more than 150 million people  
97 per year [6,7]. In addition, UTIs are the third most frequent healthcare-associated infections (HAIs),  
98 with approximately one-third of all deaths associated to HAIs [8]. Globally, deaths attributable to and  
99 associated with ABR in UTIs in 2019 were approximately 65,000 and 250,000, respectively [2,7].  
100 UTI is the second most frequent reason for using ABs in the community, which can contribute to the  
101 emergence of multi-drug resistant (MDR) bacteria [9]. The prevalence of MDR bacteria – defined as  
102 bacteria with nonsusceptibility to at least one agent in  $\geq 3$  antimicrobial categories [10] – associated  
103 with UTI has increased worldwide, thus limiting the therapeutic options for the treatment of infections  
104 caused by those microorganisms [11,12,13].

105  
106 In community-acquired UTIs, AB treatment is usually prescribed empirically. The selection of the  
107 empirical AB is based on surveillance mechanisms addressing the frequency of uropathogens and  
108 their antimicrobial resistance profiles. However, culture and susceptibility data for community UTI  
109 infections are unavailable in many LIMCs regions such as East Africa, mainly due to limited health  
110 service funding, and paucity of microbiology laboratory capacities including limited skilled personnel  
111 [2,3,4]. These data are critical for prescribing the appropriate empirical AB, which could contribute  
112 to reducing the emergence of MDR bacteria and therefore UTI-associated complications such as  
113 pyelonephritis or bacteraemia through more effective treatment [15].

114  
115 The main goals of this study are, therefore, to describe the proportion of microbiologically confirmed  
116 UTI in symptomatic patients who attended clinics in Kenya, Tanzania, and Uganda, to characterize  
117 the main uropathogenic bacteria responsible and their antimicrobial resistance profiles, and to  
118 estimate the proportion of MDR bacteria associated with UTIs. The findings presented here can input  
119 to UTI empirical treatment guidelines in East Africa, helping to prevent the AMR-associated  
120 complications and deaths.

121

## 122 **2. Methods**

### 123 **2.1. Study design, patient selection, and sample size**

124 The sample collection took place between April 2019 and November 2020 in Kenya, Tanzania, and  
125 Uganda in different levels of health facilities and locations (Table S1). The study included adults and  
126 children ( $\geq 2$  years) with signs and symptoms of UTI (detailed description for inclusion of patients  
127 are shown in the supplementary material (Method S1). Self-collected mid-stream clean catch urine  
128 samples were obtained from each patient, as described previously [5]. Patients were classified

129 according to their stay at the recruitment health facilities as outpatient (visits with no overnight stay)  
130 or inpatient (overnight or longer stay). A total of 7,583 patients with symptomatic UTI were recruited  
131 from Kenya (n=1,903), Tanzania (n=3,852), and Uganda (n=1,828) (Figure 1).

132

## 133 **2.2. Urine culture and biochemical identification of isolates**

134 A standard disposable sterile plastic loop was used to inoculate 1µl or 10µl of mid-stream urine  
135 sample onto cysteine–lactose–electrolyte–deficient (CLED), sheep blood (SBA), and MacConkey  
136 agar plates (Oxoid, Basingstoke, UK) [16]. After 18-24 hours of incubation at 37°C under aerobic  
137 conditions, cultures were quantified. Microbiologically confirmed urinary tract infection (hereafter  
138 UTI positive samples) was defined by the presence of  $>10^4$  colony-forming units per millilitre of one  
139 or two uropathogens. Contaminated samples ( $> 10^4$  CFU/mL growth of more than two different  
140 uropathogens or any growth of  $< 10^4$  CFU/mL) and those with no microbial growth were considered  
141 UTI negative. In samples containing two possible uropathogens, only the predominant or the most  
142 probable uropathogen (subjected to the evaluation by an experienced clinical microbiologist) was  
143 included in the analysis of the data.

144

145 In-house methods were used to identify Gram-negative bacteria and included: colonial morphology  
146 on CLED, Blood, and MacConkey agar (Oxoid, Basingstoke, UK), and Triple Sugar Iron agar,  
147 Sulphur Indole and Motility, Citrate, Oxidase, Urease, Voges-Proskauer and Methyl Red tests.  
148 Coagulase, Catalase, Bile-esculin, and Bacitracin-Sulfamethoxazole disc susceptibility tests were  
149 used to confirm the presence of Gram-positive bacteria, which were identified using colony  
150 morphology on SBA.

151

## 152 **2.3. Antimicrobial susceptibility testing**

153 Antimicrobial susceptibility testing (AST) was performed by the conventional Kirby–Bauer disk  
154 diffusion method according to Clinical and Laboratory Standards Institute (CLSI) M02 document  
155 [17]. The discs (Oxoid, Basingstoke, UK) tested were ampicillin (10µg), amoxicillin/clavulanic acid  
156 (20/10µg), cefoxitin (30µg), tetracycline (30µg), trimethoprim (5µg), ciprofloxacin (5µg),  
157 gentamicin (10µg), nitrofurantoin (100µg), ceftriaxone (30µg), ceftazidime (30µg), erythromycin  
158 (15µg), linezolid (10µg) and vancomycin (30µg). The susceptibility or non-susceptibility (resistance)  
159 to the tested ABs was determined by using the breakpoints (zone diameter interpretive criteria)  
160 indicated in the M100 document of CLSI guidelines [18], as further detailed in supplementary Method  
161 S2. Those isolates that showed intermediate resistance to a given AB were considered resistant to

162 such AB. Prediction of possible extended-spectrum  $\beta$ -lactamase (ESBL) producers was based on  
163 ceftazidime and/or ceftriaxone resistance, following the criteria indicated in the CLSI guidelines [18].

164

#### 165 **2.4. Definition and analysis of multidrug resistance**

166 MDR bacteria were defined as isolates resistant to at least one agent in three or more classes of  
167 antimicrobial agents, following the European Centre for Disease Prevention and Control (ECDC)  
168 guidelines [10], with some modifications as specified in supplementary Method S3. MDR rates were  
169 calculated by considering the number of MDR isolates divided by the total isolates where valid MDR  
170 data were obtained.

171

#### 172 **2.5. Patient characteristics**

173 A questionnaire was conducted with all patients (or their parents/guardians) which captured  
174 sociodemographic factors including age, gender, and other factors (e.g. education, marital status and  
175 household socioeconomic factors). Selected variables are shown in Table 1.

176

#### 177 **2.6. Data management and analysis**

178 Data were captured using paper forms and electronically, using Epicollect5 mobile application  
179 (<https://five.epicollect.net>) [19]. Urinalysis, AST and MDR data was linked to the questionnaire data  
180 using anonymous patient identifiers. AB susceptibility/MDR rates were calculated in R Statistical  
181 Software (v4.1.1; R Core Team 2021). Descriptive analysis and  $\chi^2$ -testing with false discovery rate  
182 correction (Benjamini and Yekutieli 2001) were conducted in STATA 16 (StataCorp. 2019. Stata  
183 Statistical Software: Release 16. College Station, TX: StataCorp LLC).

184

#### 185 **2.7. Quality control**

186 *Escherichia coli* ATCC 25922, *E. coli* NCTC 13353 (CTX-M-15 ESBL producer), *Staphylococcus*  
187 *aureus* ATCC 25923, *S. aureus* NCTC 13552 (*mecC*; MRSA), *Pseudomonas aeruginosa* ATCC  
188 49189, *Proteus mirabilis* NCTC 10975, and *Enterococcus faecium* ATCC 51559 (*vanA*; vancomycin  
189 resistant) were used as reference strains for quality control of culture, biochemical identification, and  
190 antimicrobial susceptibility tests.

191

### 192 **3. Results**

#### 193 **3.1. Study participants and samples**

194 A consort diagram of patient recruitment and analysis is shown in Figure 1. A total of 7,583 urine  
195 samples from non-repetitive patients with suspected UTI were collected in Kenya, Tanzania, and

196 Uganda, of which 7,574 were categorized as either UTI-negative or UTI-positive, according to the  
197 results of the urine cultures. Of a total of 2,653 biochemically identified isolates, we obtained a valid  
198 AST result for 2,357 bacteria, which were subsequently included in the AST and MDR analysis.

199

### 200 **3.2. Demographic features**

201 Participant characteristics are shown in Table 1. Most were adult outpatients (89.9%) and females  
202 (77%). The modal age category was 25 to 34 years, and those aged 18-34 years contributed more than  
203 half (54.7%) of the total sample.

204

### 205 **3.3. Proportion of microbiologically confirmed UTI**

206 The overall proportion of microbiologically confirmed UTI across the three countries was 35.0%,  
207 being significantly higher in inpatients than in outpatients, in females, in patients recruited in higher-  
208 level facilities, and among patients over 65 years old (Table S3). Kenya reported a UTI proportion of  
209 54.1%, which was higher than the proportion of 29.2% and 27.5% found in Tanzania and Uganda,  
210 respectively (Table S3).

211

### 212 **3.4. Identity of isolates from UTI**

213 A total of 2,653 isolates were characterised from urine samples of UTI-positive patients, 2,416 from  
214 outpatients and 237 from inpatients, of which 94.9% corresponded to bacteria, 1.1% to yeast, and  
215 4.0% to isolates whose biochemical identification was not available. Among the bacterial isolates  
216 (n=2,518), 62.7% and 37.3% were Gram-negative and Gram-positive bacteria, respectively, of which  
217 91.2% (n=2,297) were identified to at least the genus level.

218

219 Considering the three countries together (Table 2), *E. coli* was the predominant species (37.0%),  
220 followed by *Staphylococcus* spp. (26.3%), *Klebsiella* spp. (5.8%), and *Enterococcus* spp. (5.5%). By  
221 country, Kenya showed higher proportion of *Staphylococcus* spp. than Tanzania and Uganda, while  
222 Uganda showed higher proportion of *E. coli* than Kenya and Tanzania. Globally, *E. coli*,  
223 *Staphylococcus* spp., *Enterococcus* spp. and *Pseudomonas* spp. were more represented in samples  
224 from outpatients than inpatients, while proportions of *Klebsiella* spp. and *Acinetobacter* spp. were  
225 higher in samples from inpatients (Table S4).

226

### 227 **3.5. Regional burden of MDR in UTI pathogens**

228 Of a total of 2,266 isolates included in the AST and MDR analysis (Figure 1), n=1,153 (50.9%) were  
229 categorized as MDR. By country, MDR rates were similar in Tanzania (60.9%) and Uganda (57.5%)



230 while Kenya had a lower MDR rate (36.9%) (Table 3). Considering all countries together, the  
231 proportion of uropathogens that were classified as MDR was significantly higher in isolates from  
232 inpatients, those recruited in lower-level facilities, and in male patients (Table 3). By country, MDR  
233 proportions in Kenya and Tanzania were higher in males than in females, but this relationship was  
234 reversed in Uganda. By pathogen, *Staphylococcus* spp. showed the higher rates of MDR (60.3%),  
235 followed by *E. coli* (52.2%), *Klebsiella* spp. (50.6%), *Enterococcus* spp. (38.1%), and other  
236 *Enterobacterales* (31.2%) (Table 4). Within each pathogen group, isolates from inpatients or males  
237 exhibited higher MDR rates than isolates from outpatients and females, respectively (Table 4).

238

### 239 **3.6. Antibiotic susceptibility and MDR in *Enterobacterales***

240 The overall resistance rates of *Enterobacterales* ranged from 71.6% for trimethoprim to 7.5% for  
241 nitrofurantoin. The proportion of isolates with an ESBL and MDR were 31.4% and 49.5%,  
242 respectively (Table 5). Within bacterial groups, the resistance rates of the *E. coli* isolates ranged from  
243 74.4% for trimethoprim to 4.1 % for nitrofurantoin (Table 5), with an ESBL and MDR proportion of  
244 29.3% and 52.2%, respectively. *Klebsiella* spp. isolates exhibited resistance rates between 93.5% for  
245 ampicillin to 14.3% for nitrofurantoin (Table 5) and ESBL and MDR rates of 53.9% and 50.6%,  
246 respectively. The resistance rates of other *Enterobacterales* ranged from 61.8% for trimethoprim to  
247 15.1% for gentamicin, displaying ESBL and MDR rates of 21.7% and 30.9%, respectively.

248

249 *E. coli* from Kenya were less likely to be resistant to ampicillin, amoxicillin/clavulanic acid,  
250 trimethoprim, ciprofloxacin, ceftriaxone, and ceftazidime than those from Tanzania and Uganda,  
251 while in Tanzania, *E. coli* resistance to nitrofurantoin was higher than the other countries (Table S5).  
252 In addition, MDR and ESBL were less common among *E. coli* isolates from Kenya than those from  
253 Tanzania and Uganda, while MDR *Klebsiella* spp. were less represented in Uganda than in Tanzania.  
254 Regarding other *Enterobacterales*, isolates from Kenya were significantly less likely to be resistant  
255 to ampicillin, amoxicillin/clavulanic acid, ceftriaxone and ceftazidime than those from Tanzania and  
256 Uganda, and also showed lower ESBL and MDR rates. Ugandan isolates showed significantly higher  
257 rates of resistance to nitrofurantoin than isolates from other countries (Table S5).

258

259 The proportion of resistant isolates was generally higher in inpatients (Table S6) than outpatients  
260 (Table S7). Prevalence of ESBL and MDR among inpatient isolates was higher among *E. coli*,  
261 *Klebsiella* spp. and other *Enterobacterales* than those from outpatients (Table S6 and S7).

262

### 263 **3.7. Antibiotic susceptibility and MDR in *Staphylococci* and *Enterococci***



264 The proportion of resistant *Staphylococcus* spp. isolates ranged from 5.5 % for nitrofurantoin to  
265 81.8% for trimethoprim, with a MDR prevalence of 60.3% (Table 5). The cefoxitin resistance  
266 indicating methicillin resistance among staphylococci was 37.5%, 42.4% and 42.9% for Kenya,  
267 Tanzania, and Uganda respectively (Table S8). *Staphylococcus* spp. from Kenya showed a higher  
268 proportion of linezolid-resistant isolates (23.4%) than the other two countries (5.5%-7.5%) (Table  
269 S8). Isolates from Tanzania had the greatest proportion with MDR (72.3%).

270

271 For *Enterococcus* spp., the overall resistance rates ranged from 8.8% for linezolid to 69.8% for  
272 erythromycin, with a MDR prevalence of 38.1% (Table 5). Comparisons among countries revealed  
273 that *Enterococcus* sp. isolates from Kenya were less resistant to tetracycline and nitrofurantoin, and  
274 more resistant to linezolid than isolates from Tanzania and Uganda, with no significant differences in  
275 MDR rates (Table S8).

276

277 *Staphylococcus* spp. isolates from inpatients (Table S9) showed higher resistance than isolates from  
278 outpatients (Table S10), except for ABs ciprofloxacin, trimethoprim and tetracycline, displaying also  
279 increased MDR (72.1% vs. 59.5%) (Tables S9 and S10). *Enterococcus* spp. from inpatients were  
280 more resistant to ciprofloxacin, erythromycin and tetracycline, and showed higher MDR than  
281 outpatients (68.8% vs. 34.4%) (Tables S9 and S10).

282

#### 283 **4. Discussion**

284 This study samples the patterns of ABR in bacteria associated with UTIs in symptomatic patients in  
285 East Africa. Our main finding is that ABR of the main uropathogens isolated from UTIs (*E. coli*,  
286 *Staphylococcus* spp., *Klebsiella* spp., and *Enterococcus* spp.) are severely high. Further,  
287 approximately half of the bacterial pathogens isolated from UTIs have MDR. That rate was much  
288 higher among inpatients (which we assume are predominantly hospital-acquired UTI) than in  
289 outpatients (which we assume are predominantly community-acquired UTIs), as has been described  
290 previously [20,21]. These alarming data provide further empirical evidence to enrich the findings of  
291 recent studies describing the high morbidity and mortality burden from ABR in Eastern sub-Saharan  
292 Africa [2].

293

294 The high proportion of MDR in UTI could suggest a previous record of inappropriate AB use in  
295 Kenya, Tanzania, and Uganda, which is often considered to be one of the key drivers of AMR. This  
296 could be caused by (a) the scarcity of microbiology and AB susceptibility data in this region [2,3,4]  
297 which can hamper the management of more appropriate empirical treatment for UTIs, and (b) AB

298 self-treatment and the prevalence of over-the-counter sales of ABs in the community, widespread in  
299 LMICs [22,23,24]. Suboptimal management of treatment and the community transmission of MDR  
300 bacteria promoted by crowded and less sanitary living conditions, more common in low- and middle-  
301 income countries (LMICs) [25], could explain the high proportions of MDR bacteria and the tendency  
302 in the study cohort to come straight to clinic [26].

303

304 In addition, we found differences among countries, with Kenya presenting lower percentage of MDR  
305 bacteria (36.9%) than Tanzania (60.9%) and Uganda (57.5%). Worthy of special attention are the  
306 high MDR rates of *E. coli* (>66.0%) found in Tanzania and Uganda, as well as MDR *Klebsiella*  
307 (62.2%), *Staphylococcus* (72.3%) and *Enterococcus* (46.6%) species observed in Tanzania, which  
308 were much higher than in the other countries. These results emphasise the importance of  
309 implementing or reviewing country-specific empirical AB recommendations, which could increase  
310 AB efficacy and reduce the burden of AMR according to the resistance rates of each country [27].

311

312 Globally, our results fill a crucial data gap which we hope will: (a) feed into guidelines for UTI  
313 empirical treatment, (b) provide vital surveillance data for East Africa and indeed the wider Sub-  
314 Saharan region, a region with one of the highest ABR-mortality burdens in the world, and c)  
315 contribute to development of interventions to monitor and counter the threat of ABR across the region  
316 through improved diagnostics and surveillance.

317

318 The sparsity of data about the prevalence of resistance for key pathogen–antibiotic combinations in  
319 LMICs is a limiting factor for drafting empirical treatment guidelines which can promote appropriate  
320 prescription hence hindering the selection of the resistant pathogens [2,3,4]. In this study, we have  
321 found a high prevalence of the most insidious AB-pathogen combinations i.e. third-generation  
322 cephalosporin (3GC)-resistant *E. coli* (29.3%), fluoroquinolone-resistant *E. coli* (45.8%), 3GC-  
323 resistant *Klebsiella* spp. (53.9%), methicillin-resistant staphylococci (39.7%), fluoroquinolone-  
324 resistant *Enterococcus* spp. (40.1%), and vancomycin-resistant *Enterococcus* spp. (37.2%). However,  
325 we observed systematic variations across country settings, with the Kenyan samples showing the  
326 lowest rate of resistance to these ABs, which suggest that recommendations for using a specific  
327 empirical AB should be tailored according to each country [27]. The high proportion of  
328 fluoroquinolone-resistant *E. coli* and fluoroquinolone-resistant *Enterococcus* spp. found in this study,  
329 which are in the top six of the most lethal AB-combination in UTI [7], advise against the empirical  
330 use of this AB, whose use in treatment of uncomplicated UTI is no longer recommended by WHO  
331 [28,29]. The clinical guidelines of Tanzania and Uganda recommended ciprofloxacin as first or

332 second line ABs for the treatment of uncomplicated UTI in outpatients [30,31,32], which could  
333 explain the higher fluoroquinolone resistance observed in these two countries than those observed in  
334 Kenya.

335 Methicillin-resistant *S. aureus* was the most lethal drug-pathogen combination in 2019 in the world  
336 [2], being in the top ten of resistance-attributable deaths in UTI [7]. Although in our study  
337 staphylococci were not analysed to species level, we found an overall rate of methicillin (cefoxitin)  
338 resistance of 39.7%. This contrasts with global estimations in sub-Saharan Africa, which has been  
339 recently described as one of the lowest in the world (5%) [2]. Our study has revealed *Staphylococcus*  
340 spp. as the second most frequent genus in UTI, which is in line with current evidence that point  
341 towards a major role of this species as a common cause of UTI [33,34,35]. Although we cannot rule  
342 out contamination with *Staphylococcus* spp. in UTI samples, the fact that nearly 2 of every 3 isolates  
343 were MDR, and  $\approx 40\%$  were resistant to cefoxitin, should be considered for managing *Staphylococcus*  
344 spp. as true causing agents of UTI.

345

346 Amoxicillin/clavulanic acid is among the ABs commonly used to treat uncomplicated UTI. In this  
347 study, we found a high level of resistance (37.3%-47.1%) to amoxicillin/clavulanic acid in  
348 *Enterobacterales*, which could endanger its future empirical use for treatment of UTIs [36] as  
349 happened with amoxicillin alone, whose use in uncomplicated UTI is no longer recommended [29].  
350 In addition, the overall resistance to the folate pathway inhibitor trimethoprim was exceptionally high  
351 (53.9%-74.4%) in isolates from order *Enterobacterales*, while resistance to nitrofurantoin was low.  
352 This trend has been reported in UTIs worldwide, which has led to the prioritization of the use of  
353 nitrofurantoin over trimethoprim as the first-line treatment for UTI [37], including East Africa  
354 [30,31,32]. In 2021, however, the WHO added single-agent trimethoprim as a recommendation for  
355 the treatment of uncomplicated UTI [29], whose empirical use in East Africa (with a trimethoprim-  
356 resistance *E. coli* rate of until 84.1% in Tanzania), would make that AB poorly effective for the  
357 treatment of UTI in that region.

358

359 The study has some limitations. In the design of the HATUA we endeavoured to provide a consistent  
360 study framework across the three countries and the three sites within each country where patients  
361 were recruited and their samples were processed and analysed. Standardization of methods and  
362 operating procedures were applied across the consortium [5] and used by the Kenyan, Tanzanian, and  
363 Ugandan chapters of HATUA. However, even with these in place we cannot rule out that some biases  
364 in sampling practices or patient populations studied will have occurred.

365

366 Within each country three sites were chosen that had three distinct socio-demographical  
367 characteristics and represented a different type of site. This was done in order capture the burden of  
368 AMR in UTIs across different community settings in each country. Whilst each country selected sites  
369 that were representative of each site type, and provided some level of sociodemographic  
370 comparability across countries for the study, there is variation that a study of this scale introduces  
371 that means that the populations are not equivalent due to geographic, climatic, ethnic and cultural  
372 factors. In this regard we note that across the three countries there are differences in the demographic  
373 profiles of the patients recruited. For example, in Kenya more recruitment occurred at higher level  
374 health facilities, and the cohort had a greater proportion of patients under the age of 35 years in  
375 comparison to those of the other countries. We cannot therefore exclude the introduction of bias that  
376 may influence some of the observed microbiological results and some of the differences seen between  
377 countries. Recognising this, the interpretation of the results should reflect that they do not necessarily  
378 represent true country-level differences across the region, as the sampling within the countries is  
379 limited to three sites and is not representative of the countries as a whole.

380

381 With such a large, multi-site study, and need for comparability, there have been some inevitable trade-  
382 offs between depth and breadth, and as a result for most of the isolates, only their identification to  
383 genus level is shown. As samples from outpatients were self-collected, there was a risk of  
384 contamination in the samples, which could help explain the high levels of *Staphylococcus* spp. found  
385 in this study. Although a wide range of the most commonly used/relevant ABs for UTI in the region  
386 was tested, this did not include all possible ABs, which could have led to an underestimation of the  
387 true MDR proportions, and therefore our estimates of the burden of AMR on patients with UTIs are  
388 conservative.

389

## 390 **5. Conclusions**

391 This multi-site standardised study describes how approximately half of UTI patients that attended to  
392 our recruitment centres in Kenya, Tanzania, and Uganda exhibit MDR bacteria. Several of the most  
393 hazardous pathogen-antibiotic combinations (third-generation cephalosporins and fluoroquinolones  
394 resistant *E. coli*; methicillin-resistant staphylococci (MRS); third-generation cephalosporin-resistant  
395 *K. pneumoniae*; vancomycin-resistant enterococci; multi-drug resistant bacteria) were detected at  
396 high proportions in UTI, which severely limits the effectiveness of currently used ABs to treat this  
397 common infection. These findings should feed directly into guidelines for empiric AB treatment of  
398 UTI in East Africa. More broadly, we emphasize the need for urgent investment in routine AMR  
399 surveillance programs, expansion of diagnostic laboratory capacities and diagnostic algorithms to

400 facilitate antimicrobial stewardship and call for greater commitment from policymakers to counter  
401 the threat of AMR.

402

### 403 **Acknowledgements**

404 We thank all the patients who participated in the HATUA study and the field and laboratory teams in  
405 each of the three countries.

406

### 407 **Funding**

408 HATUA is a Global Context Consortia Award (MR/S004785/1) funded by the National Institute for  
409 Health Research, Medical Research Council, and the Department of Health and Social Care. This UK  
410 funded award is part of the EDCTP2 programme supported by the European Union.

411

### 412 **Competing interests**

413 None

414

### 415 **Ethical approval**

416 The studies involving human participants were reviewed and approved by University of St Andrews,  
417 UK (number MD14548, 10/09/19); National Institute for Medical Research, Tanzania (number 2831,  
418 updated 26/07/19); CUHAS/BMC Research Ethics and Review Committee (number CREC  
419 /266/2018, updated on 02/2019); Mbeya Medical Research and Ethics Committee (number SZEC-  
420 2439/R.A/V.1/303030); Kilimanjaro Christian Medical College, Tanzania (number 2293, updated  
421 14/08/19); Uganda National Council for Science and Technology (number HS2406, 18/06/18);  
422 Makerere University, Uganda (number 514, 25/04/18); and Kenya Medical Research Institute  
423 (04/06/19, Scientific and Ethics Review Committee (SERU) number  
424 KEMRI/SERU/CMR/P00112/3865 V.1.2). The patients/participants provided their written informed  
425 consent to participate in this study.


426

427

428

429

**Figure 1.** Consort diagram describing HATUA patient recruitment and processing and analysis of their urine samples.





**Table 1.** Characteristics of the patients with symptoms of UTI at the time of recruitment

<b>Variables/Country</b>	<b>Kenya n (%)</b>	<b>Tanzania n (%)</b>	<b>Uganda n (%)</b>	<b>Total n (%)</b>
<b>Patient type</b>				
Outpatient	1754(92.4)	3552(92.2)	1815(99.5)	7121(94.0)
Inpatient	144(7.6)	300(7.8)	9(0.5)	453(6.0)
<b>Gender</b>				
Male	348(18.3)	1097(28.5)	295(16.2)	1740(23.0)
Female	1550(81.7)	2754(71.5)	1529(83.8)	5833(77.0)
Missing	NA	1(0.0)	NA	1(0.0)
<b>Age in years</b>				
<18	79(4.2)	343(8.9)	62(3.4)	484(6.4)
18-24	493(26.0)	718(18.6)	573(31.4)	1784(23.6)
25-34	837(44.1)	950(24.7)	573(31.4)	2360(31.2)
35-44	294(15.5)	550(14.3)	304(16.7)	1148(15.2)
45-54	97(5.1)	425(11.0)	173(9.5)	695(9.2)
55-64	43(2.3)	321(8.3)	71(3.9)	435(5.7)
65-74	35(1.8)	281(7.3)	43(2.4)	359(4.7)
75 and above	20(1.1)	261(6.8)	22(1.2)	303(4.0)
Missing	0(0)	3(0.1)	3(0.2)	6(0.1)
<b>Hospital level<sup>1</sup></b>				
Level 2 (low)	0(0)	309 (8.0)	394(21.6)	703(9.3)
Level 3	384(20.2)	2152(55.9)	1023(56.1)	3559(47.0)
Level 4	486(25.6)	366(9.5)	143(7.8)	995(13.1)
Level 5 /6 (high)	1028(54.2)	1025(26.6)	263(14.4)	2316(30.6)
Missing	0(0)	0(0)	1(0.1)	1(0.0)
<b>TOTAL</b>	<b>1898 (100.0)</b>	<b>3852 (100.0)</b>	<b>1824 (100.0)</b>	<b>7574 (100.0)</b>

<sup>1</sup>In all three countries, lower levels (1-3) refer to primary care, dispensaries, or community health centres. Level 4 typically refers to primary referral facilities or specialist health care facilities. Level 5 (and 6 in Kenyan) are higher level/tertiary facilities.

**Table 2.** Distribution of significant microorganisms isolated from specimens of symptomatic patients with UTI (UTI positive patients), according to the country.

Country	Kenya			Tanzania			Uganda			All 3 countries		
	n	% <sup>1</sup>	Prev (%) <sup>2</sup>	n	%	Prev (%)	n	%	Prev (%)	n	%	Prev (%)
<i>Escherichia coli</i>	317	30.9	16.7	402	35.8	10.4	263	52.4	14.4	982	37.0	13.0
<i>Klebsiella</i> spp.	0	0	0	90	8.0	2.3	64	12.7	3.5	154	5.8	2.0
<i>Proteus</i> spp.	69	6.7	3.6	13	1.2	0.3	15	3.0	0.8	97	3.7	1.3
<i>Acinetobacter</i> spp.	8	0.8	0.4	19	1.7	0.5	5	1.0	0.3	32	1.2	0.4
<i>Pseudomonas</i> spp.	8	0.8	0.4	41	3.6	1.1	1	0.2	0.1	50	1.9	0.7
Miscellaneous Gram-negative <sup>3</sup>	101	9.8	5.3	111	9.9	2.9	52	10.4	2.9	264	10.0	3.5
<i>Staphylococcus</i> spp.	387	37.7	20.4	220	19.6	5.7	91	18.1	5.0	698	26.3	9.2
<i>Enterococcus</i> spp.	86	8.4	4.5	58	5.2	1.5	3	0.6	0.2	147	5.5	1.9
Miscellaneous Gram-positive <sup>4</sup>	31	3.0	1.6	55	4.9	1.4	8	1.6	0.4	94	3.5	1.2
Yeast	2	0.2	0.1	28	1.1	0.7	0	0.0	0.0	30	1.1	0.4
Missing species data	18	1.8	0.9	87	7.7	2.3	0	0.0	0.0	105	4.0	1.4
Total	1027	100	54.1	1124	100	29.2	502	100	27.5	2653	100	35.0

<sup>1</sup>% = percentage of isolates corresponding to that species, from that country (for example in the first column, calculated by  $317/1027*100$ ).

<sup>2</sup>Prev = prevalence proportion (e.g. number of *E. coli* isolates with respect to the total number of urine specimens that were cultured in that country). For example, the third column is calculated by  $317/1898*100$ .

<sup>3</sup>Across all three countries, this comprises *Aeromonas* spp. (n=1), *Citrobacter* spp. (n=16), *Enterobacter* spp. (n=24), *Moraxella* spp. (n=1), *Morganella* spp. (n=6), *Pantoea* spp. (n=2), *Providencia* spp. (n=2), *Salmonella* spp. (n=2), *Serratia* spp. (n=4), *Shigella* spp. (n=1), *Stenotrophomonas* spp. (n=1), and undetermined Gram-negative bacteria (n=113)

<sup>4</sup>Across all three countries, this comprises *Bacillus* spp. (n=19), *Clostridium* spp. (n=1), *Corynebacterium* spp. (n=1), *Lactobacillus* spp. (n=6), *Streptococcus* spp. (n=50), and undetermined Gram-positive bacteria (n=17).

**Table 3.** Prevalence of multi-drug resistant (MDR) bacteria in UTI positive samples by country, and according to patient type, hospital level, gender, and age.

Variable	MDR <sup>1</sup> n (%)			
	Kenya n (%)	Tanzania n (%)	Uganda n (%)	All countries n (%)
<b>Patient type</b>				
Outpatient	291(35.4)	466(58.8)	258(57.3)	1015(49.2)
Inpatient	36(56.3)	100(73.0)	2(100)	138(68.0)
$\chi^2$ , p value	9.7, p=0.014	9.24, p=0.019	0.25, p=1.000	25.1, p<0.001
<b>Facility level</b>				
Level 2/3	55(35.7)	328(59.2)	188(54.3)	571(54.2)
Level 4	109 (37.0)	55(59.1)	26(76.5)	190(45.2)
Level 5 /6	168(38.1)	183(64.9)	46(63.9)	397(49.9)
$\chi^2$ , p value	0.27, p=1.000	2.67, p=0.728	7.62, p=0.183	10.7, p<0.001
<b>Sex</b>				
Male	40(42.1)	174(68.5)	30(53.6)	244(60.2)
Female	287(36.3)	392(58.2)	230(58.1)	909(48.9)
$\chi^2$ , p value	1.41, p=0.740	9.85, p=0.030	0.24, p=1.000	18.8, p<0.001
<b>Age</b>				
<18	20(45.5)	42(64.6)	6(66.7)	68(57.3)
18-24	84(34.1)	95(56.9)	73(52.1)	252(45.5)
25-34	135(35.3)	116(62.0)	84(57.5)	335(46.8)
35-44	53(39.3)	70(54.3)	44(66.7)	167(50.6)
45-54	19(50.0)	59(59.0)	35(60.3)	113(57.6)
55-64	9(56.3)	53(66.3)	9(64.3)	71(64.5)
65-74	8(44.4)	66(66.0)	3(30.0)	77(60.2)
75 and above	4(40.0)	65(64.4)	4(57.1)	73(61.9)
$\chi^2$ , p value	8.81, p=0.740	6.71, p=0.96	7.76, p=1.000	35.3, p<0.001
<b>TOTAL MDR</b>	327(36.9)	566(60.9)	260(57.5)	1153(50.9)
Total isolates	885	929	452	2266

<sup>1</sup> MDR was defined as non-susceptibility to at least one antimicrobial agent in three or more antimicrobial categories, according to the ECDC guidelines [10] with some modifications, as described in the methods section (see Table S2). % is the prevalence of MDR, calculated by dividing the number of isolates that are MDR (n) by the number of isolates tested for MDR of each category and country.

**Table 4.** Prevalence of multi-drug resistant (MDR) bacteria in UTI positive samples for selected species, according to patient type, age, and gender.

	<i>Escherichia coli</i>	<i>Klebsiella spp.</i>	MDR <sup>1</sup> n (%) Other <i>Entero- bacterales</i> <sup>2</sup>	<i>Staphylococcus spp.</i>	<i>Enterococcus spp.</i>
<b>Patient type</b>					
Outpatient	460 (50.8)	57 (44.9)	39 (28.3)	389 (59.5)	45 (34.4)
Inpatient	53 (69.7)	21 (77.8)	9 (56.3)	31 (72.1)	11 (68.8)
<b><math>\chi^2</math> p value</b>	9.36, p=0.006	8.36, p=0.020	4.01, p=0.120	2.11, p=0.803	5.58, p=0.064
<b>Age</b>					
Adult	481 (51.7)	71 (49.7)	43 (30.9)	403 (59.9)	52 (37.7)
Child	31 (62.0)	6 (60.0)	5 (33.3)	17 (70.8)	4 (44.4)
<b><math>\chi^2</math> p value</b>	1.64, p=0.367	0.09, p=1.000	0.01, p=1.000	0.71, p=0.970	0.01, p=1.000
<b>Gender</b>					
Male	107 (71.3)	37 (63.8)	23 (44.2)	43 (64.2)	17 (58.6)
Female	406 (48.8)	41 (42.7)	25 (24.5)	377 (59.8)	39 (33.1)
<b><math>\chi^2</math> p value</b>	25.7, p<0.001	5.61, p=0.048	5.35, p=0.113	0.39, p=0.970	5.14, p=0.064
<b>Total MDR</b>	513 (52.2)	78 (50.6)	48 (31.2)	420 (60.3)	56 (38.1)
Total isolates	982	154	154	697	147

<sup>1</sup> MDR was defined as non-susceptibility to at least one antimicrobial agent in three or more antimicrobial categories, according to the ECDC guidelines [10] with some modifications, as described in the methods section (see Table S2). % is the prevalence of MDR, calculated by dividing the number of isolates that are MDR (n) by the number of isolates tested for MDR of each category and selected species.

<sup>2</sup>Other *Enterobacteriales* includes *Citrobacter*, *Enterobacter*, *Morganella*, *Proteus*, *Providencia*, *Pantoea*, *Salmonella*, *Serratia* and *Shigella* species.

**Table 5.** Antibiotic susceptibility, ESBL and MDR rates of *Enterobacterales* and relevant Gram-positive uropathogens

	<i>Enterobacterales</i>		<i>Escherichia coli</i>		<i>Klebsiella</i> spp.		Other <i>Enterobacterales</i> <sup>1</sup>		<i>Staphylococcus</i> spp.		<i>Enterococcus</i> spp.	
	% <sup>2</sup>	n <sup>3</sup>	%	n	%	n	%	n	%	n	%	n
<b>Ampicillin</b>	65.9	1289	64.5	981	93.5	154	46.8	154	NA <sup>4</sup>	NA	NA	NA
<b>Amoxicillin/ clavulanic acid</b>	40.7	1276	38.1	970	60.1	153	37.3	153	NA	NA	NA	NA
<b>Ceftazidime</b>	24.0	1277	22.7	971	41.2	153	15.7	153	NA	NA	NA	NA
<b>Ceftriaxone</b>	30.2	1287	28.5	979	51.3	154	20.1	154	NA	NA	NA	NA
<b>Ciprofloxacin</b>	44.8	1289	45.8	982	43.5	154	39.2	153	38.2	696	40.1	147
<b>Gentamicin</b>	21.5	1170	22.1	900	24.8	129	14.9	141	20.9	669	NA	NA
<b>Nitrofurantoin</b>	7.5	1286	4.1	978	14.3	154	22.7	154	5.5	692	9.5	147
<b>Trimethoprim</b>	71.6	1289	74.4	981	63.0	154	62.3	154	81.8	696	NA	NA
<b>Cefoxitin</b>	NA	NA	NA	NA	NA	NA	NA	NA	39.7	692	NA	NA
<b>Linezolid</b>	NA	NA	NA	NA	NA	NA	NA	NA	15.9	661	8.8	136
<b>Erythromycin</b>	NA	NA	NA	NA	NA	NA	NA	NA	72.5	662	69.8	139
<b>Tetracycline</b>	NA	NA	NA	NA	NA	NA	NA	NA	48.0	671	50.3	145
<b>Vancomycin</b>	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	37.2	137
<b>ESBL<sup>5</sup></b>	31.4	1290	29.3	982	53.9	154	22.1	154	NA	NA	NA	NA
<b>MDR<sup>6</sup></b>	49.5	1290	52.2	982	50.6	154	31.2	154	60.3	697	38.1	147

<sup>1</sup> Other *Enterobacterales* includes *Citrobacter*, *Enterobacter*, *Morganella*, *Proteus*, *Providencia*, *Pantoea*, *Salmonella*, *Serratia* and *Shigella* species.

<sup>2</sup> % is the frequency of non-susceptible isolates, expressed in percentage.

<sup>3</sup> n is the total number of isolates that were tested for a specific antibiotic.

<sup>4</sup> not applicable (NA), the antibiotic was not tested in those isolates.

<sup>5</sup> Possible producers of extended-spectrum  $\beta$ -lactamase (ESBL) were determined by considering the resistance to antibiotics Ceftazidime and Ceftriaxone, according to CLSI guidelines [17].

<sup>6</sup> Multi drug-resistance (MDR) was defined as non-susceptibility to at least one antimicrobial agent in three or more antimicrobial categories, according to the ECDC guidelines [10] with some modifications, as described in the methods section.

## **Appendix. Supplementary materials**

### **Method S1. Patient selection/Case definition**

The study included adults and children ( $\geq 2$  years) with signs and symptoms of urinary tract infections. Patients attended to the health facilities to seek treatment for UTI-like symptoms or for other causes that gave the doctor reason to believe that they might also (or actually) have a UTI.

Specifically, the study enrolled: (a) pregnant women with fever and at least one of the following symptoms, lower abdominal pain, flank/back pain, or strong-smelling urine; (b) pregnant women with at least one urinary symptom, i.e., dysuria, pyuria or haematuria; (c) non-pregnant women or men with fever and at least one of the following symptoms, lower abdominal pain, flank/back pain or strong-smelling urine; (d) non-pregnant women or men with at least one urinary symptom, i.e., frequency, dysuria, pyuria, haematuria or urgency [1,2,3]. In addition, the study enrolled all children aged two years and above that complied with at least one of the following criteria: (a) fever and at least one of: vomiting, abdominal pain, flank/back pain, strong-smelling urine or enuresis; (b) at least one of these urinary symptoms: dysuria, pyuria, hematuria, urgency or frequency; (c) or child with at least two of: costovertebral angle tenderness, abdominal or suprapubic tenderness to palpation, palpable bladder or dribbling/poor stream [4].

### **Method S2. Antimicrobial susceptibility testing (AST)**

The susceptibility or non-susceptibility (resistance) to the tested antibiotics was determined by using the breakpoints (zone diameter interpretive criteria) indicated in the CLSI guidelines [5] with the following modifications. For nitrofurantoin and linezolid, the European Committee on Antimicrobial Susceptibility Testing [6] breakpoints were used. For *Acinetobacter* spp., susceptibility to amoxicillin/clavulanic acid and trimethoprim was determined using the breakpoints for *Enterobacterales*. For *Staphylococcus* spp., methicillin resistance (non-susceptibility to ceftiofur) was calculated using the breakpoints for *S. epidermidis* and *Staphylococcus* spp. For *Pseudomonas* spp., breakpoints for *Pseudomonas aeruginosa* were applied.

### **Method S3. Definition and analysis of Multidrug resistance (MDR)**

MDR bacteria were defined as isolates resistant to at least one agent in three or more classes of antimicrobial agents, following the European Centre for Disease Prevention and Control (ECDC) guidelines [7], with some modifications. Thus, nitrofurantoin and trimethoprim, two antibiotics routinely used for treating UTIs that are not included in the ECDC tables [7], were also considered for estimating MDR (Table S2). In addition, for those species/genera not incorporated in the ECDC,



i.e. *Salmonella*, *Shigella* and *Streptococcus*, the MDR rates were calculated following the same rule as described above, but considering the resistance to a selected pool of tested antibiotics (Table S2). Those *Staphylococcus* spp. isolates that were resistant to cefoxitin (methicillin-resistant), were not automatically considered MDR, and were subjected to the rule of being resistant to at least one agent in three or more classes of antimicrobial agents. In those isolates with intrinsic resistance to a given antibiotic, such antibiotic was not considered for calculating MDR. By means of this approach, isolates from UTIs were classified as MDR or non-MDR. MDR rates were calculated by considering the number of MDR isolates divided by the total isolates where valid MDR data were obtained.

## References

- [1] Geerlings SE. Clinical Presentations and Epidemiology of Urinary Tract Infections. *Microbiol Spectr* 2016;4:10.1128/microbiolspec.UTI-0002-2012. <https://doi.org/10.1128/microbiolspec.UTI-0002-2012>.
- [2] Bonkat G, Pickard R, Bartoletti R, Bruyère F, Geerlings SE, Wagenlehner F, et al. EAU guidelines on urological infections. *European Association of Urology* 2017;18:22-6
- [3] Orenstein R, Wong ES. Urinary tract infections in adults. *Am Fam Physician* 1999;59:1225-1237. PMID: 10088877.
- [4] Ginsburg CM, McCracken GH Jr. Urinary tract infections in young infants. *Pediatrics* 1982;69:409-12. PMID: 7070887.
- [5] Magiorakos AP, Srinivasan A, Carey RB, Carmeli Y, Falagas ME, Giske CG, et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. *Clin Microbiol Infect* 2012;18:268-81. <https://doi.org/10.1111/j.1469-0691.2011.03570.x>.
- [6] CLSI. 2021. Performance standards for antimicrobial susceptibility testing, M100, 31st ed. Clinical and Laboratory Standards Institute, Wayne, PA.
- [7] EUCAST. 2021. The European Committee on Antimicrobial Susceptibility Testing. Breakpoint tables for interpretation of MICs and zone diameters. Version 11.0.

**Table S1.** Patient recruitment sites and healthcare facilities in Kenya, Tanzania, and Uganda.

Country/site	Number of facilities	Source of funding	Levels recruited from <sup>1</sup>
<b>Kenya</b>			
Makueni	1	Public	5
Nairobi	4	Public and private	3, 4, 5, 6
Nanyuki	1	Public	4
<b>Tanzania</b>			
Kilimanjaro/Moshi	3	Public and private	2, 3, 5
Mbeya	2	Public and private	3, 4
Mwanza	5	Public and private	2, 3, 5
<b>Uganda</b>			
Mbarara	3	Public	3, 5
Nakapiripirit	3	Public	2, 3
Nakasongola	3	Public and private	3, 4

<sup>1</sup> Levels of facilities are identified in each country following the Kenya Health Policy 2014-2013 ([http://publications.universalhealth2030.org/uploads/kenya\\_health\\_policy\\_2014\\_to\\_2030.pdf](http://publications.universalhealth2030.org/uploads/kenya_health_policy_2014_to_2030.pdf)), Tanzania fifth health sector strategic plan (HSSP V) 2021-2026 ([https://p4h.world/en/node/11813#:~:text=2026%20%7C%20P4H%20Network-,Tanzania%20fifth%20health%20sector%20strategic%20plan%20\(HSSPV\)%2D%202021%2D2026,coverage%20\(UHC\)%20by%202030](https://p4h.world/en/node/11813#:~:text=2026%20%7C%20P4H%20Network-,Tanzania%20fifth%20health%20sector%20strategic%20plan%20(HSSPV)%2D%202021%2D2026,coverage%20(UHC)%20by%202030)) and the Ugandan Hospital and Health Centre IV census survey 2014

In all three countries, lower levels (1-3) refer to primary care, dispensaries or community health centres. Level 4 typically refers to primary referral facilities or specialist health care facilities. Level 5 (and 6 in Kenyan) are higher level/tertiary facilities.

**Table S2.** Antibiotics considered for MDR calculations.

Gram negative	Amoxicillin/ clavulanate (AMC)	Ampicillin (AMP)	Ceftazidime/ Ceftriaxone (CAZ/CRO)	Ciprofloxacin (CIP)	Gentamicin (GEN)	Nitrofurantoin (NIT)	Trimethoprim (TMP)
<i>E. coli</i>	AMC	AMP	CAZ/CRO	CIP	GEN	NIT	TMP
<i>Shigella spp.</i>	AMC	AMP	CAZ/CRO	CIP	GEN	NIT	TMP
<i>Proteus spp.</i>	AMC	AMP	CAZ/CRO	CIP	GEN	NIT	TMP
<i>Salmonella spp.</i>	AMC	AMP	CAZ/CRO	CIP	GEN	NIT	TMP
<i>Serratia spp.</i>	-	-	CAZ/CRO	CIP	GEN	NIT	TMP
<i>Klebsiella spp.</i>	AMC	-	CAZ/CRO	CIP	GEN	NIT	TMP
<i>Citrobacter spp.</i>	-	-	CAZ/CRO	CIP	GEN	NIT	TMP
<i>Enterobacter spp.</i>	-	-	CAZ/CRO	CIP	GEN	NIT	TMP
<i>Morganella spp.</i>	-	-	CAZ/CRO	CIP	GEN	NIT	TMP
<i>Pantoea spp.</i>	-	-	CAZ/CRO	CIP	GEN	NIT	TMP
<i>Providencia spp.</i>	-	-	CAZ/CRO	CIP	GEN	NIT	TMP
<i>Acinetobacter spp.</i>	-	-	CAZ/CRO	CIP	GEN	-	TMP
<i>Pseudomonas spp.</i>	-	-	CAZ	CIP	GEN	-	-

Gram positive	Cefoxitin (FOX)	Erythromycin (ERY)	Linezolid (LNZ)	Ciprofloxacin (CIP)	Gentamicin (GEN)	Nitrofurantoin (NIT)	Trimethoprim (TMP)	Tetracycline (TCY)	Vancomycin (VAN)
<i>Staphylococcus spp.</i>	FOX	ERY	-	CIP	GEN	NIT	TMP	TCY	-
<i>Enterococcus spp.</i>	-	ERY	LNZ	CIP	-	NIT	-	TCY	VAN
<i>Streptococcus spp.</i>	-	ERY	LNZ	-	-	NIT	-	TCY	VAN

**Table S3.** Prevalence of UTI according to patient type, gender, hospital level age, and country.

Variables/Country	N/% with UTI			
	Kenya n (%) <sup>1</sup>	Tanzania n (%) <sup>1</sup>	Uganda n (%) <sup>1</sup>	All 3 countries n (%) <sup>1</sup>
<b>Patient type</b>				
Outpatient	943(53.8)	974(27.4)	499(27.5)	2416(33.9)
Inpatient	84(58.3)	150(50.0)	3(33.3)	237(52.3)
$\chi^2$ , p value <sup>2</sup>	0.94, p=0.690	67.2, p<0.001	0.1, p=1.000	62.48, p<0.001
<b>Gender</b>				
Male	111(31.9)	305(27.8)	64(21.7)	480(27.6)
Female	916(59.1)	818(29.7)	438(28.6)	2172(37.2)
$\chi^2$ , p value <sup>2</sup>	69.1, p<0.001	15.2, p=0.004	7.7, p=0.217	190.6, p<0.001
<b>Hospital level</b>				
Level 2	0	88(28.5)	126(32.0)	214(30.4)
Level 3	162(42.2)	585(27.2)	259(25.3)	1006(28.3)
Level 4	336(69.1)	104(28.4)	37(25.9)	477(47.9)
Level 5/6	529(51.4)	347(33.9)	80(30.4)	956(41.3)
$\chi^2$ , p value <sup>2</sup>	83.6, p<0.001	3.8, p=0.312	5.6, p=0.14	56.7, p<0.001
<b>Age</b>				
<18	51(64.6)	75(21.9)	11(17.7)	137(28.3)
18-24	286(58.0)	211(29.4)	155(27.1)	652(36.5)
25-34	436(52.1)	243(25.6)	159(27.8)	838(35.5)
35-44	148(50.3)	150(27.3)	75(24.7)	373(32.5)
45-54	49(50.5)	111(26.1)	62(35.8)	222(31.9)
55-64	19(44.2)	95(29.6)	17(23.9)	131(30.1)
65-74	23(65.7)	111(39.5)	12(27.9)	146(40.7)
75 and above	15(75.0)	127(48.7)	9(40.9)	151(49.8)
$\chi^2$ , p value <sup>2</sup>	17.2, p=0.045	80.2, p<0.001	12.7, p=0.22	56.6, p<0.001
<b>Total</b>	1027(54.1)	1124(29.2)	502(27.5)	2653(35.0)

<sup>1</sup> % is the prevalence of UTI positive samples, calculated by dividing the number of UTI positive samples by the total number of urine samples cultured (n). A sample was considered UTI-positive if presented  $>10^4$  CFU/mL of one or two uropathogens.

<sup>2</sup> Ch-squared testing adjusted for false discovery rate (as described in the methods).

**Table S4.** Distribution of significant microorganisms isolated from specimens of symptomatic patients with UTI (UTI positive patients), according to the country and the type of patient (Outpatient or Inpatient).

Country	Kenya Outpatient			Kenya Inpatient			Tanzania Outpatient			Tanzania Inpatient			Uganda Outpatient			Uganda Inpatient			All 3 countries Outpatient			All 3 countries Inpatient		
	n	% <sup>1</sup>	Prev (%) <sup>2</sup>	n	%	Prev (%)	n	%	Prev (%)	n	%	Prev (%)	n	%	Prev (%)	n	%	Prev (%)	n	%	Prev (%)	n	%	Prev (%)
<i>Escherichia coli</i>	294	31.2	16.9	23	27.4	16.0	350	35.9	9.9	52	34.7	17.3	262	52.5	14.4	1	33.3	11.1	906	37.5	12.8	76	32.1	16.8
<i>Klebsiella</i> spp.	0.0	0.0	0.0	0.0	0.0	0.0	64	6.6	1.8	26	17.3	8.7	63	12.6	3.5	1	33.3	11.1	127	5.3	1.8	27	11.4	6.0
<i>Proteus</i> spp.	66	7.0	3.8	3	3.6	2.1	12	1.2	0.3	1	0.7	0.3	15	3.0	0.8	0	0.0	0.0	93	3.8	1.3	4	1.7	0.9
<i>Acinetobacter</i> spp.	7	0.7	0.4	1	1.2	0.7	14	1.4	0.4	5	3.3	1.7	5	1.0	0.3	0	0.0	0.0	26	1.1	0.4	6	2.5	1.3
<i>Pseudomonas aeruginosa</i>	6	0.6	0.3	2	2.4	1.4	25	2.6	0.7	16	10.7	5.3	1	0.2	0.1	0	0.0	0.0	32	1.3	0.4	18	7.6	4.0
Miscellaneous Gram-negative <sup>3</sup>	87	9.2	5.0	14	16.7	9.7	94	9.7	2.6	17	11.3	5.7	51	10.2	2.8	1	33.3	11.1	232	9.6	3.3	32	13.5	7.1
<i>Staphylococcus</i> spp.	359	38.1	20.6	28	33.3	19.4	205	21.0	5.8	15	10.0	5.0	91	18.2	5.0	0	0.0	0.0	655	27.1	9.2	43	18.1	9.5
<i>Enterococcus</i> spp.	81	8.6	4.7	5	6.0	3.5	47	4.8	1.3	11	7.3	3.7	3	0.6	0.2	0	0.0	0.0	131	5.4	1.9	16	6.8	3.5
Miscellaneous Gram-positive <sup>4</sup>	28	3.0	1.6	3	3.6	2.1	54	5.5	1.5	1	0.7	0.3	8	1.6	0.4	0	0.0	0.0	90	3.7	1.3	4	1.7	0.9
Yeast	2	0.2	0.1	0	0.0	0.0	25	2.6	0.7	3	2.0	1.0	0	0.0	0.0	0	0.0	0.0	27	1.1	0.4	3	1.3	0.7
Missing species data	13	1.4	0.7	5	6.0	3.5	84	8.6	2.4	3	2.0	1.0	0	0.0	0.0	0	0.0	0.0	97	4.0	1.4	8	3.4	1.8
Total	943	100	53.8	84	100	58.3	974	100	27.4	150	100	50.0	499	100	27.5	3	100	33.3	2416	100	33.9	237	100	52.3

<sup>1</sup>%= percentage of isolates corresponding to that species, from that country and patient type (for example in the first column, calculated by 294/943\*100)

<sup>2</sup>Prev= prevalence proportion (e.g. number of *E. coli* isolates with respect to the total number of urine specimens that were cultured in that country, for that type of patient. For example, the third column is calculated by 294/1752\*100.

<sup>3</sup>This comprises *Aeromonas* spp. (n=1), *Citrobacter* spp. (n=16), *Enterobacter* spp. (n=24), *Moraxella* spp. (n=1), *Morganella* spp. (n=6), *Pantoea* spp. (n=2), *Providencia* spp. (n=2), *Salmonella* spp. (n=2), *Serratia* spp. (n=4), *Shigella* spp. (n=1), *Stenotrophomonas* spp. (n=1), and undetermined Gram-negative bacteria (n=115)

<sup>4</sup> This comprises *Bacillus* spp. (n=19), *Clostridium* spp. (n=1), *Corynebacterium* spp. (n=1), *Lactobacillus* spp. (n=6), *Streptococcus* spp. (n=50), and undetermined Gram-positive bacteria (n=16).

**Table S5.** Antibiotic susceptibility, ESBL and MDR rates of *Enterobacteriales*

	<i>Escherichia coli</i>								<i>Klebsiella spp.</i>								Other <i>Enterobacteriales</i> <sup>1</sup>							
	Kenya		Tanzania		Uganda		Three countries		Kenya		Tanzania		Uganda		Three countries		Kenya		Tanzania		Uganda		Three countries	
	% <sup>2</sup>	n <sup>3</sup>	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n
<b>Ampicillin</b>	21.8	317	87.1	402	81.7	262	64.5	981	NA	NA	92.2	90	95.3	64	93.5	154	11.5	78	84.3	51	80.0	25	46.8	154
<b>Amoxicillin-clavulanic acid</b>	17.4	316	43.0	402	56.3	252	38.1	970	NA	NA	58.9	90	61.9	63	60.1	153	10.3	78	64.7	51	66.7	24	37.3	153
<b>Ceftazidime</b>	8.5	317	28.1	402	31.7	252	22.7	971	NA	NA	47.8	90	31.7	63	41.2	153	3.8	78	23.5	51	37.5	24	15.7	153
<b>Ceftriaxone</b>	9.2	315	32.1	402	46.2	262	28.5	979	NA	NA	52.2	90	50.0	64	51.3	154	5.1	78	25.5	51	56.0	25	20.1	154
<b>Ciprofloxacin</b>	30.0	317	57.0	402	47.9	263	45.8	982	NA	NA	55.6	90	26.6	64	43.5	154	33.8	77	45.1	51	44.0	25	39.2	153
<b>Gentamicin</b>	16.9	314	27.6	402	19.0	184	22.1	900	NA	NA	31.1	90	10.3	39	24.8	129	11.8	76	21.6	51	7.1	14	14.9	141
<b>Nitrofurantoin</b>	2.9	313	6.7	402	1.5	263	4.1	978	NA	NA	18.9	90	7.8	64	14.3	154	10.3	78	31.4	51	44.0	25	22.7	154
<b>Trimethoprim</b>	57.9	316	84.1	402	79.5	263	74.4	981	NA	NA	68.9	90	54.7	64	63.0	154	65.4	78	62.7	51	52.0	25	62.3	154
<b>ESBL<sup>4</sup></b>	9.5	317	32.6	402	48.3	263	29.3	982	NA	NA	53.3	90	54.7	64	53.9	154	6.4	78	29.4	51	56.0	25	22.1	154
<b>MDR<sup>5</sup></b>	22.7	317	66.4	402	66.2	263	52.2	982	NA	NA	62.2	90	34.4	64	50.6	154	19.2	78	43.1	51	44.0	25	31.2	154

<sup>1</sup> Other *Enterobacteriales* includes *Citrobacter*, *Enterobacter*, *Morganella*, *Proteus*, *Providencia*, *Pantoea*, *Salmonella*, *Serratia* and *Shigella* species.

<sup>2</sup> % is the frequency of non-susceptible isolates, expressed in percentage.

<sup>3</sup> n is the total number of isolates that were tested for a specific antibiotic.

<sup>4</sup> Possible producers of extended-spectrum  $\beta$ -lactamase (ESBL) were determined by considering the resistance to antibiotics Ceftazidime and Ceftriaxone, according to CLSI guidelines [17].

<sup>5</sup> Multi drug-resistance (MDR) was defined as non-susceptibility to at least one antimicrobial agent in three or more antimicrobial categories, according to the ECDC guidelines [10] with some modifications, as described in the methods section.



**Table S6.** Antibiotic susceptibility, ESBL and MDR rates of relevant *Enterobacterales* isolated from outpatients with UTI.

Country	<i>Escherichia coli</i> (outpatient)								<i>Klebsiella</i> spp. (outpatient)								Other <i>Enterobacterales</i> <sup>1</sup> (outpatient)							
	Kenya		Tanzania		Uganda		Three countries		Kenya		Tanzania		Uganda		Three countries		Kenya		Tanzania		Uganda		Three countries	
	% <sup>2</sup>	n <sup>3</sup>	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n
<b>Ampicillin</b>	21.1	294	85.7	350	81.6	261	63.5	905	NA	NA	93.8	64	95.2	63	94.5	127	11.0	73	82.5	40	80	25	44.2	138
<b>Amoxicillin/ clavulanic acid</b>	17.1	293	39.1	350	56.6	251	36.8	894	NA	NA	54.7	64	61.3	62	57.9	126	9.6	73	57.5	40	66.7	24	33.6	137
<b>Ceftazidime</b>	7.5	294	22.6	350	31.9	251	20.2	895	NA	NA	35.9	64	30.6	62	33.3	126	1.4	73	15.0	40	37.5	24	11.7	137
<b>Ceftriaxone</b>	8.2	293	26.0	350	46.0	261	26.0	904	NA	NA	42.2	64	49.2	63	45.7	127	2.7	73	17.5	40	56.0	25	16.7	138
<b>Ciprofloxacin</b>	29.6	294	54.0	350	47.7	262	44.3	906	NA	NA	50	64	25.4	63	37.8	127	31.9	72	42.5	40	44.0	25	37.2	137
<b>Gentamicin</b>	14.7	292	24.3	350	19.0	184	19.7	826	NA	NA	23.4	64	10.3	39	18.4	103	9.9	71	15.0	40	7.1	14	11.2	125
<b>Nitrofurantoin</b>	2.1	291	4.9	350	1.5	262	3.0	903	NA	NA	15.6	64	7.9	63	11.8	127	11.0	73	32.5	40	44.0	25	23.2	138
<b>Trimethoprim</b>	59.0	293	83.4	350	79.4	262	74.4	905	NA	NA	60.9	64	54.0	63	57.5	127	64.4	73	62.5	40	52.0	25	61.6	138
<b>ESBL<sup>4</sup></b>	8.5	294	26.6	350	48.1	262	26.9	906	NA	NA	43.8	64	54.0	63	48.8	127	2.7	73	22.5	40	56.0	25	18.1	138
<b>MDR<sup>5</sup></b>	21.4	294	64.0	350	66.0	262	50.8	906	NA	NA	56.3	64	33.3	63	44.9	127	16.4	73	40	40	44.0	25	28.3	138

<sup>1</sup> Other *Enterobacterales* includes *Citrobacter*, *Enterobacter*, *Morganella*, *Proteus*, *Providencia*, *Pantoea*, *Salmonella*, *Serratia* and *Shigella* species.

<sup>2</sup> % is the frequency of non-susceptible isolates, expressed in percentage.

<sup>3</sup> n is the total number of isolates that were tested for a specific antibiotic.

<sup>4</sup> Possible producers of extended-spectrum  $\beta$ -lactamase (ESBL) were determined by considering the resistance to antibiotics Ceftazidime and Ceftriaxone, according to CLSI guidelines [17].

<sup>5</sup> Multi drug-resistance (MDR) was defined as non-susceptibility to at least one antimicrobial agent in three or more antimicrobial categories, according to the ECDC guidelines [10].

**Table S7.** Antibiotic susceptibility, ESBL and MDR rates of relevant *Enterobacterales* isolated from inpatients with UTI.

Country	<i>Escherichia coli</i> (inpatient)								<i>Klebsiella</i> spp. (inpatient)								Other <i>Enterobacterales</i> <sup>1</sup> (inpatient)					
	Kenya		Tanzania		Uganda		Three countries		Kenya		Tanzania		Uganda		Three countries		Kenya		Tanzania		Three Countries <sup>2</sup>	
	% <sup>3</sup>	n <sup>4</sup>	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n
<b>Ampicillin</b>	30.4	23	96.2	52	100	1	76.3	76	NA	NA	88.5	26	100	1	88.9	27	20	5	90.9	11	68.8	16
<b>Amoxicillin/ clavulanic acid</b>	21.7	23	69.2	52	0	1	53.9	76	NA	NA	69.2	26	100	1	70.4	27	20	5	90.9	11	68.8	16
<b>Ceftazidime</b>	21.7	23	65.4	52	0	1	51.3	76	NA	NA	76.9	26	100	1	77.8	27	40	5	54.5	11	50	16
<b>Ceftriaxone</b>	22.7	22	73.1	52	100	1	58.7	75	NA	NA	76.9	26	100	1	77.8	27	40	5	54.5	11	50	16
<b>Ciprofloxacin</b>	34.8	23	76.9	52	100	1	64.5	76	NA	NA	69.2	26	100	1	70.4	27	60	5	54.5	11	56.3	16
<b>Gentamicin</b>	45.5	22	50	52	NA <sup>5</sup>	NA	48.6	74	NA	NA	50	26	NA	NA	50.0	26	40	5	45.5	11	43.8	16
<b>Nitrofurantoin</b>	13.6	22	19.2	52	0	1	17.3	75	NA	NA	26.9	26	0	1	25.9	27	0	5	27.3	11	18.8	16
<b>Trimethoprim</b>	43.5	23	88.5	52	100	1	75.0	76	NA	NA	88.5	26	100	1	88.9	27	80	5	63.6	11	68.8	16
<b>ESBL<sup>6</sup></b>	21.7	23	73.1	52	100	1	57.9	76	NA	NA	76.9	26	100	1	77.8	27	60	5	54.5	11	56.3	16
<b>MDR<sup>7</sup></b>	39.1	23	82.7	52	100	1	69.7	76	NA	NA	76.9	26	100	1	77.8	27	60	5	54.5	11	56.3	16

<sup>1</sup> Other *Enterobacterales* includes *Citrobacter*, *Enterobacter*, *Morganella*, *Proteus*, *Providencia*, *Pantoea*, *Salmonella*, *Serratia* and *Shigella* species.

<sup>2</sup> No *Enterobacterales* were isolated from Uganda inpatients

<sup>3</sup> % is the frequency of non-susceptible isolates, expressed in percentage.

<sup>4</sup> n is the total number of isolates that were tested for a specific antibiotic.

<sup>5</sup> NA: not applicable.

<sup>6</sup> Possible producers of extended-spectrum  $\beta$ -lactamase (ESBL) were determined by considering the resistance to antibiotics Ceftazidime and Ceftriaxone, according to CLSI guidelines [17].

<sup>7</sup> Multi drug-resistance (MDR) was defined as non-susceptibility to at least one antimicrobial agent in three or more antimicrobial categories, according to the ECDC guidelines [10] with some modifications, as described in the methods section.

**Table S8.** Antibiotic susceptibility and MDR rates of relevant Gram-positive uropathogens.

	<i>Staphylococcus spp.</i>								<i>Enterococcus spp.</i>							
	Kenya		Tanzania		Uganda		Three countries		Kenya		Tanzania		Uganda		Three countries	
	% <sup>1</sup>	n <sup>2</sup>	%	n	%	n	%	n	%	n	%	n	%	n	%	n
<b>Cefoxitin</b>	37.5	384	42.4	217	42.9	91	39.7	692	NA	NA	NA	NA	NA	NA	NA	NA
<b>Ciprofloxacin</b>	29.4	385	50.9	220	45.1	91	38.2	696	33.7	86	48.3	58	66.7	3	40.1	147
<b>Nitrofurantoin</b>	5.5	381	6.4	220	3.3	91	5.5	692	4.7	86	15.5	58	33.3	3	9.5	147
<b>Trimethoprim</b>	78.4	385	85.0	220	87.9	91	81.8	696	NA	NA	NA	NA	NA	NA	NA	NA
<b>Gentamicin</b>	18.2	385	24.1	220	26.6	64	20.9	669	NA	NA	NA	NA	NA	NA	NA	NA
<b>Linezolid</b>	23.4	376	5.5	220	7.7	65	15.9	661	14.6	82	0.0	52	0.0	2	8.8	136
<b>Erythromycin</b>	68.7	377	79.1	220	72.3	65	72.5	662	67.1	82	74.5	55	50.0	2	69.8	139
<b>Tetracycline</b>	41.5	386	53.6	220	67.7	65	48.0	671	37.6	85	69.0	58	50.0	2	50.3	145
<b>Vancomycin</b>	NA	NA	NA	NA	NA	NA	NA	NA	42.5	80	30.9	55	0.0	2	37.2	137
<b>MDR<sup>3</sup></b>	54.7	386	72.3	220	54.9	91	60.3	697	32.6	86	46.6	58	33.3	3	38.1	147

<sup>1</sup> % is the frequency of non-susceptible isolates, expressed in percentage.

<sup>2</sup> n is the total number of isolates that were tested for a specific antibiotic.

<sup>3</sup> Multi drug-resistance (MDR) was defined as non-susceptibility to at least one antimicrobial agent in three or more antimicrobial categories, according to the ECDC guidelines [10] with some modifications, as described in the methods section.

**Table S9.** Antibiotic susceptibility, ESBL and MDR rates of *Staphylococcus* spp. and *Enterococcus* spp. isolated from outpatients with UTI.

Country	<i>Staphylococcus</i> spp. (outpatient)								<i>Enterococcus</i> spp. (outpatient)							
	Kenya		Tanzania		Uganda		Three countries		Kenya		Tanzania		Uganda		Three countries	
	% <sup>1</sup>	n <sup>2</sup>	%	n	%	n	%	n	%	n	%	n	%	n	%	n
<b>Cefoxitin</b>	35.1	356	43.1	202	42.9	91	38.7	649	NA <sup>3</sup>	NA	NA	NA	NA	NA	NA	NA
<b>Ciprofloxacin</b>	28.3	357	50.7	205	45.1	91	37.7	653	32.1	81	42.6	47	66.7	3	36.6	131
<b>Nitrofurantoin</b>	4.5	353	5.9	205	3.3	91	4.8	649	4.9	81	19.1	47	33.3	3	10.7	131
<b>Trimethoprim</b>	77.9	357	85.4	205	87.9	91	81.6	653	NA	NA	NA	NA	NA	NA	NA	NA
<b>Gentamicin</b>	15.1	357	23.4	205	26.6	64	19.0	626	NA	NA	NA	NA	NA	NA	NA	NA
<b>Linezolid</b>	20.9	349	4.9	205	7.7	65	14.2	619	15.6	77	0.0	41	0.0	2	10.0	120
<b>Erythromycin</b>	67.4	350	78.0	205	72.3	65	71.5	620	64.9	77	70.5	44	50.0	2	66.7	123
<b>Tetracycline</b>	40.8	358	53.2	205	67.7	65	47.6	628	35.0	80	63.8	47	50.0	2	45.7	129
<b>Vancomycin</b>	NA	NA	NA	NA	NA	NA	NA	NA	41.3	75	29.5	44	0.0	2	36.4	121
<b>MDR<sup>4</sup></b>	53.1	358	72.7	205	54.9	91	59.5	654	30.9	81	40.4	47	33.3	3	34.4	131

<sup>1</sup> % is the frequency of non-susceptible isolates, expressed in percentage.

<sup>2</sup> n is the total number of isolates that were tested for a specific antibiotic.

<sup>3</sup> NA: not applicable.

<sup>4</sup> Multi drug-resistance (MDR) was defined as non-susceptibility to at least one antimicrobial agent in three or more antimicrobial categories, according to the ECDC guidelines [10] with some modifications, as described in the methods section.

**Table S10.** Antibiotic susceptibility, ESBL and MDR rates of *Staphylococcus* spp. and *Enterococcus* spp. isolated from inpatients with UTI.

Country	<i>Staphylococcus</i> spp. (inpatient)						<i>Enterococcus</i> spp. (inpatient)					
	Kenya		Tanzania		Three countries <sup>1</sup>		Kenya		Tanzania		Three countries <sup>1</sup>	
	% <sup>2</sup>	n <sup>3</sup>	%	n	%	n	%	n	%	n	%	n
<b>Cefoxitin</b>	67.9	28	33.3	15	55.8	43	NA <sup>4</sup>	NA	NA	NA	NA	NA
<b>Ciprofloxacin</b>	42.9	28	53.3	15	46.5	43	60.0	5	72.7	11	68.8	16
<b>Nitrofurantoin</b>	17.9	28	13.3	15	16.3	43	0.0	5	0.0	11	0.0	16
<b>Trimethoprim</b>	85.7	28	80.0	15	83.7	43	NA	NA	NA	NA	NA	NA
<b>Gentamicin</b>	57.1	28	33.3	15	48.8	43	NA	NA	NA	NA	NA	NA
<b>Linezolid</b>	55.6	27	13.3	15	40.5	42	0.0	5	0.0	11	0.0	16
<b>Erythromycin</b>	85.2	27	93.3	15	88.1	42	100	5	90.9	11	93.8	16
<b>Tetracycline</b>	50.0	28	60.0	15	53.5	43	80.0	5	90.9	11	87.5	16
<b>Vancomycin</b>	NA	NA	NA	NA	NA	NA	60.0	5	36.4	11	43.8	16
<b>MDR<sup>5</sup></b>	75.0	28	66.7	15	72.1	43	60.0	5	72.7	11	68.8	16

<sup>1</sup> No *Staphylococcus* or *Enterococcus* were isolated from Uganda inpatients

<sup>2</sup>% is the frequency of non-susceptible isolates, expressed in percentage.

<sup>3</sup> n is the total number of isolates that were tested for a specific antibiotic.

<sup>4</sup> NA: not applicable.

<sup>5</sup> Multi drug-resistance (MDR) was defined as non-susceptibility to at least one antimicrobial agent in three or more antimicrobial categories, according to the ECDC guidelines [10] with some modifications, as described in the methods section.

## References (Journal of Antimicrobial Agents 40 references max.).

- [1] World Health Organization. Antimicrobial resistance, <https://www.who.int/news-room/fact-sheets/detail/antimicrobial-resistance>; 2021 [accessed 8 March 2023].
- [2] Antimicrobial Resistance Collaborators. Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. *Lancet* 2022;399:629-655. [https://doi.org/10.1016/S0140-6736\(21\)02724-0](https://doi.org/10.1016/S0140-6736(21)02724-0)
- [3] Iskandar K, Molinier L, Hallit S, Sartelli M, Hardcastle TC, Haque M, et al. Surveillance of antimicrobial resistance in low- and middle-income countries: a scattered picture. *Antimicrob Resist Infect Control* 2021;10:63. <https://doi.org/10.1186/s13756-021-00931-w>.
- [4] Dunachie SJ, Day NP, Dolecek C. The challenges of estimating the human global burden of disease of antimicrobial resistant bacteria. *Curr Opin Microbiol* 2020;57:95-101. <https://doi.org/10.1016/j.mib.2020.09.013>
- [5] Asimwe BB, Kiiru J, Mshana SE, Neema S, Keenan K, Kesby M, et al. Protocol for an interdisciplinary cross-sectional study investigating the social, biological and community-level drivers of antimicrobial resistance (AMR): Holistic Approach to Unravel Antibacterial Resistance in East Africa (HATUA). *BMJ Open* 2021;11:e041418. <https://doi.org/10.1136/bmjopen-2020-041418>
- [6] Öztürk R, Murt A. Epidemiology of urological infections: a global burden. *World J Urol* 2020;38:2669-2679. <https://doi.org/10.1007/s00345-019-03071-4>.
- [7] Li X, Fan H, Zi H, Hu H, Li B, Huang J, et al. Global and Regional Burden of Bacterial Antimicrobial Resistance in Urinary Tract Infections in 2019. *J Clin Med* 2022;11:2817. <https://doi.org/10.3390/jcm11102817>.
- [8] Klevens RM, Edwards JR, Richards CL Jr, Horan TC, Gaynes RP, Pollock DA, et al. Estimating health care-associated infections and deaths in U.S. hospitals, 2002. *Public Health Rep* 2007;122:160-6. <https://doi.org/10.1177/003335490712200205>.
- [9] Malcolm W, Fletcher E, Kavanagh K, Deshpande A, Wiuff C, Marwick C, et al. Risk factors for resistance and MDR in community urine isolates: population-level analysis using the NHS Scotland Infection Intelligence Platform. *J Antimicrob Chemother* 2018;73:223-230. <https://doi.org/10.1093/jac/dkx363>.



- [10] Magiorakos AP, Srinivasan A, Carey RB, Carmeli Y, Falagas ME, Giske CG, et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. *Clin Microbiol Infect* 2012;18:268-81. <https://doi.org/10.1111/j.1469-0691.2011.03570.x>.
- [11] Mazzariol A, Bazaj A, Cornaglia G. Multi-drug-resistant Gram-negative bacteria causing urinary tract infections: a review. *J Chemother* 2017;29:2-9. <https://doi.org/10.1080/1120009X.2017.1380395>.
- [12] Kaye KS, Gupta V, Mulgirigama A, Joshi AV, Scangarella-Oman NE, Yu K, et al. Antimicrobial Resistance Trends in Urine Escherichia coli Isolates From Adult and Adolescent Females in the United States From 2011 to 2019: Rising ESBL Strains and Impact on Patient Management. *Clin Infect Dis* 2021;73:1992-99. <https://doi.org/10.1093/cid/ciab560>.
- [13] Walker E, Lyman A, Gupta K, Mahoney MV, Snyder GM, Hirsch EB. Clinical Management of an Increasing Threat: Outpatient Urinary Tract Infections Due to Multidrug-Resistant Uropathogens. *Clin Infect Dis* 2016;63:960-5. <https://doi.org/10.1093/cid/ciw396>.
- [14] Hooton TM. Clinical practice. Uncomplicated urinary tract infection. *N Engl J Med* 2012;366:1028-37. <https://doi.org/10.1056/NEJMcp1104429>.
- [15] Costelloe C, Metcalfe C, Lovering A, Mant D, Hay AD. Effect of antibiotic prescribing in primary care on antimicrobial resistance in individual patients: systematic review and meta-analysis. *BMJ* 2010;340:c2096. <https://doi.org/10.1136/bmj.c2096>.
- [16] Koneman, EW, Allen SD, Janda W, Schreckenberger P, Winn W. Diagnostic microbiology. In: *The Nonfermentative Gram-Negative Bacilli*, Philadelphia: Lippincott-Raven Publishers; 1997, p. 253–320.
- [17] CLSI. 2018. Performance Standards for Antimicrobial Disk Susceptibility Tests, M02, 13th ed. Clinical and Laboratory Standards Institute, Wayne, PA.
- [18] CLSI. 2021. Performance standards for antimicrobial susceptibility testing, M100, 31st ed. Clinical and Laboratory Standards Institute, Wayne, PA.
- [19] Aanensen DM, Huntley DM, Feil EJ, al-Own F, Spratt BG. EpiCollect: linking smartphones to web applications for epidemiology, ecology and community data collection. *PLoS One* 2009;4:e6968. <https://doi.org/10.1371/journal.pone.0006968>.

- [20] Gajdács M, Bátori Z, Burián K. Interplay between Phenotypic Resistance to Relevant Antibiotics in Gram-Negative Urinary Pathogens: A Data-Driven Analysis of 10 Years' Worth of Antibiogram Data. *Life (Basel)* 2021;11:1059. <https://doi.org/10.3390/life11101059>.
- [21] Horcajada JP, Shaw E, Padilla B, Pintado V, Calbo E, Benito N, Gamallo R, Gozalo M, Rodríguez-Baño J; ITUBRAS group; Grupo de Estudio de Infección Hospitalaria (GEIH); Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica (SEIMC). Healthcare-associated, community-acquired and hospital-acquired bacteraemic urinary tract infections in hospitalized patients: a prospective multicentre cohort study in the era of antimicrobial resistance. *Clin Microbiol Infect* 2013 ;19:962-8. <https://doi.org/10.1111/1469-0691.12089>.
- [22] Ocan M, Obuku EA, Bwanga F, Akena D, Richard S, Ogwal-Okeng J, et al. Household antimicrobial self-medication: a systematic review and meta-analysis of the burden, risk factors and outcomes in developing countries. *BMC Public Health* 2015;15:742. <https://doi.org/10.1186/s12889-015-2109-3>.
- [23] Do NTT, Vu HTL, Nguyen CTK, Punpuing S, Khan WA, Gyapong M, et al. Community-based antibiotic access and use in six low-income and middle-income countries: a mixed-method approach. *Lancet Glob Health* 2021 9:e610-e619. [https://doi.org/10.1016/S2214-109X\(21\)00024-3](https://doi.org/10.1016/S2214-109X(21)00024-3).
- [24] Ndaki PM, Mushi MF, Mwangi JR, Konje ET, Ntinginya NE, Mmbaga BT, et al. Dispensing Antibiotics without Prescription at Community Pharmacies and Accredited Drug Dispensing Outlets in Tanzania: A Cross-Sectional Study. *Antibiotics (Basel)* 2021;10:1025. <https://doi.org/10.3390/antibiotics10081025>.
- [25] Low M, Neuberger A, Hooton TM, Green MS, Raz R, Balicer RD, et al. Association between urinary community-acquired fluoroquinolone-resistant *Escherichia coli* and neighbourhood antibiotic consumption: a population-based case-control study. *Lancet Infect Dis* 2019;19:419-428. [https://doi.org/10.1016/S1473-3099\(18\)30676-5](https://doi.org/10.1016/S1473-3099(18)30676-5).
- [26] Keenan K, Fredricks K J, Abed Al Ahad, M, et al HATUA Consortium. Unravelling patient pathways in the context of antibacterial resistance in East Africa. <https://www.researchsquare.com/article/rs-1933132/v1>.
- [27] GBD 2019 Antimicrobial Resistance Collaborators. Global mortality associated with 33 bacterial pathogens in 2019: a systematic analysis for the Global Burden of Disease Study 2019. *Lancet* 2022;400:2221-2248. [https://doi.org/10.1016/S0140-6736\(22\)02185-7](https://doi.org/10.1016/S0140-6736(22)02185-7).

- [28] World Health Organization. The selection and use of essential medicines: report of the WHO Expert Committee on Selection and Use of Essential Medicines (including the 22nd WHO model list of essential medicines and the 8th WHO model list of essential medicines for children), <https://apps.who.int/iris/handle/10665/351172>; 2021 [accessed 5 March 2023]
- [29] World Health Organization. The selection and use of essential medicines: report of the WHO Expert Committee (including the 20th WHO model list of essential medicines and the 6th model list of essential medicines for children), <https://apps.who.int/iris/handle/10665/259481>; 2017 [accessed 5 March 2023]
- [30] Clinical guidelines for the management and referral of common conditions at level 2-3: Primary Care. Nairobi: Ministry of Medical Services and Ministry of Public Health and Sanitation; 2009. ([http://guidelines.health.go.ke:8000/media/Clinical\\_Guidelines\\_Vol\\_II\\_Final.pdf](http://guidelines.health.go.ke:8000/media/Clinical_Guidelines_Vol_II_Final.pdf)).
- [31] Standard Treatment Guidelines and National essential Medicines list for Tanzania Mainland. 2017. Ministry of Health, Community, Development, Gender, Elderly and Children (<https://hssrc.tamisemi.go.tz/storage/app/uploads/public/5ab/e9b/b21/5abe9bb216267130384889.pdf>).
- [32] Uganda Clinical Guidelines 2016. National Guidelines for Management of Common Conditions. Kampala: The Republic of Uganda Ministry of Health (<https://www.prb.org/wp-content/uploads/2018/05/Uganda-Clinical-Guidelines-2016-National-Guidelines-for-Management-of-Common-Conditions.pdf>)
- [33] Kline KA, Lewis AL. Gram-Positive Uropathogens, Polymicrobial Urinary Tract Infection, and the Emerging Microbiota of the Urinary Tract. *Microbiol Spectr* 2016;4: 10.1128/microbiolspec.UTI-0012-2012. <https://doi.org/10.1128/microbiolspec.UTI-0012-2012>.
- [34] Gajdács M, Ábrók M, Lázár A, Burián K. Increasing relevance of Gram-positive cocci in urinary tract infections: a 10-year analysis of their prevalence and resistance trends. *Sci Rep* 2020;10:17658. <https://doi.org/10.1038/s41598-020-74834-y>.
- [35] Johnson B, Stephen BM, Joseph N, Asiphos O, Musa K, Taseera K. Prevalence and bacteriology of culture-positive urinary tract infection among pregnant women with suspected urinary tract infection at Mbarara regional referral hospital, South-Western Uganda. *BMC Pregnancy Childbirth* 2021;21:159. <https://doi.org/10.1186/s12884-021-03641-8>.

- [36] Martínez-Casanova J, Gómez-Zorrilla S, Prim N, Dal Molin A, Echeverría-Esnal D, Gracia-Arnillas MP, Sendra E, Güerri-Fernández R, Durán-Jordà X, Padilla E, Horcajada JP, Grau S, Proa-Psmar Group OBOT. Risk Factors for Amoxicillin-Clavulanate Resistance in Community-Onset Urinary Tract Infections Caused by *Escherichia coli* or *Klebsiella pneumoniae*: The Role of Prior Exposure to Fluoroquinolones. *Antibiotics (Basel)* 2021;10:582. <https://doi.org/10.3390/antibiotics10050582>.
- [37] Pouwels KB, Freeman R, Muller-Pebody B, Rooney G, Henderson KL, Robotham JV, Smieszek T. Association between use of different antibiotics and trimethoprim resistance: going beyond the obvious crude association. *J Antimicrob Chemother* 2018;73:1700-1707. <https://doi.org/10.1093/jac/dky031>.